BRIEF-Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
* Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
Nov 28 Wolfden Resources Corp :
* Wolfden announces non-brokered flow-through private placement of up to $300,000 Source text for Eikon: Further company coverage:
* Aclaris Therapeutics Inc - submitted a new drug application to U.S. FDA for A-101 40 percent topical solution as a treatment for seborrheic keratosis
GHAZIABAD, India, Feb 27 Struggling with customers unable to pay on time and plummeting sales, Indian small-business owner Ravi Jain fears the government's crackdown on cash will have a much larger impact than predicted by top policymakers.